NCCN Guidelines for Patients® | Ovarian Cancer - page 96

96
NCCN Guidelines for Patients
®
: Ovarian cancer
Version 1.2013
Index
Ascites
11, 13, 23–25, 35, 38
Biopsy
22–24, 26, 31–35, 37, 38
Borderline ovarian cancer
4, 7–9, 30, 37, 38, 55–57, 67
CA-125
12, 18, 48, 49, 55–57, 63–65, 67, 68
Cancer drugs
3, 29, 33, 40–51, 53, 61
Cancer grade
3, 22, 26, 27, 34, 46, 47, 77
Cancer stage
3, 22, 24–27, 29–35, 39, 42, 46–50, 76, 77
Caregivers
4, 71, 73, 74, 78, 79
Chemotherapy
3, 29, 31, 33–38, 41–44, 46–53, 61,
64–68, 71, 76, 78
IV chemotherapy
42, 43, 46, 47, 53
IP chemotherapy
42–47, 52, 53
Clinical stage
22, 31–33
Clinical trial
49–53, 64–66, 77
Complementary and alternative medicine (CAM)
45
Computed tomography (CT)
15–17, 55, 56, 65
Debulking surgery
32, 39, 65–67
Epithelial cells
4, 7
Epithelial ovarian cancer
4–9
Fertility
29, 30, 38, 55
Follow-up
3, 37, 38, 46–50, 54–57, 64, 65, 67, 78
Gene
6, 13
Hormone therapy
60–62, 76
Implants
7–9, 25, 37, 38
Magnetic resonance imaging (MRI)
15–17, 55, 56, 65
Member Institutions
92, 94, 95
Menopause
29, 30
National Comprehensive Cancer Network (NCCN)
2, 92
Observation
35, 38, 47, 50, 51, 55, 65, 67
Panel members
93
Pathologic stage
22, 46
Positron emission tomography (PET)
15, 17, 55, 56, 65
Primary chemotherapy
41, 42, 49–51
Recurrence, relapse
3, 49, 50, 59–61, 63–68
1...,86,87,88,89,90,91,92,93,94,95 97,98,99,100
Powered by FlippingBook